Octapharma Activities Prominent at the Upcoming 2017 ISTH Congress in Berlin, Germany
Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held in Berlin, Germany from 8–13 July. Octapharma is delighted to be a Platinum Sponsor of the Congress, reflecting an ongoing commitment to advancing the treatment of patients with haemophilia and von Willebrand disease (VWD).
Octapharma will play a prominent role at the ISTH Congress with activities including two sponsored scientific symposia and seven poster presentations during the scientific sessions. Abstracts of the posters will be published in the Research and Practice in Thrombosis and Haemostasis journal after the Congress.
The addition of Nuwiq®, a human cell-line derived recombinant FVIII (rFVIII) for the treatment of haemophilia A, has extended Octapharma’s established haematology portfolio of coagulation factors – wilate® (von Willebrand Factor (VWF) indicated for VWD and haemophilia A), octanate® (VWD and haemophilia A) and octanine®F (haemophilia B).
Two leading-edge symposia on new developments in bleeding management in Haemophilia A and VWD
The latest developments with Nuwiq ® , a naturally long-acting rFVIII made in human cells to protect against bleeds while addressing the risk of inhibitors in patients with haemophilia A, will be discussed in a scientific symposium, “Life without limitation: Growing experience with Nuwiq ® in patients with haemophilia A”. The symposium will be held on Sunday 9 July 2017 (16:15–17:45, Room A8). The symposium will focus on interim data from a clinical study (NuProtect) of Nuwiq® in previously untreated patients as well as clinical trial (NuPreviq) data and real-life clinical experience with the NuPreviq approach of pharmacokinetic (PK)-guided personalised prophylaxis and its potential to reduce the number of infusions and bleeding rates in patients with haemophilia A.
The latest developments with wilate ® , a high purity, double virus-inactivated VWF/FVIII concentrate containing both factors in a physiological 1:1 ratio, in VWD and haemophilia A, will be discussed in a scientific symposium, “wilate ® for a lifetime of care: Bleeding management across high-risk patient populations”. The symposium will be held on Monday 10 July 2017 (13:15–14:30, Room Paris). The symposium will focus on the treatment of high-risk patients throughout life, including patients with FVIII or VWF inhibitors, women undergoing pregnancy and delivery with VWD, and ageing VWD patients.
Seven posters presenting new data and ongoing experience across products:
Four posters on Nuwiq ® will be displayed during the Congress:
Monday 10 July, Exhibition Hall 2.2, authors present 12.00–13.15
- Efficacy and safety of Nuwiq ® (Human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures. N. Zozulya et al., Poster PB227.
- Inhibitor development and efficacy in previously untreated patients with severe haemophilia A treated with Nuwiq ® (Human-cl rhFVIII), a 4th generation recombinant FVIII of human origin. R. Liesner et al., Poster PB211.
- Long-term treatment with Nuwiq ® (Human-cl rhFVIII) in previously treated children with severe haemophilia A. A. Klukowska et al., Poster PB207.
- Pharmacokinetic guided personalised prophylaxis with Nuwiq ® (Human-cl rhFVIII) in adult patients with severe haemophilia A. C. Kessler et al., Poster PB1794.
Two posters on wilate ® will be displayed at the Congress:
Monday 10 July, Exhibition Hall 2.2, authors present 12.00–13.15
- International clinical study investigating the incidence of inhibitors in previously untreated patients with severe haemophilia A treated with a high purity FVIII/VWF concentrate in a 1:1 ratio. T. Andreeva, et al., Poster PB238.
- Surgeries in adults and children with von Willebrand’s disease – results from the ongoing study Wilate-STATE. S. Halimeh, et al., Poster PB383.
A poster describing the final results of a clinical trial in PUPs with haemophilia A treated with octanate ® , a human plasma-derived, high-purity, freeze-dried, double virus-inactivated FVIII concentrate, will be displayed at the Congress:
Wednesday 12 July, Exhibition Hall 2.2, authors present 12.00–13.15
- Final results from the PUP-GCP trial: A low inhibitor rate in previously untreated patients with severe haemophilia A treated with octanate ® . A. Klukowska, et al., Poster PB1787.
Larisa Belyanskaya, Head of IBU Haematology at Octapharma, said: “We are very excited by the results across our haematology portfolio and look forward to sharing our latest data at the ISTH 2017 Congress”.
Olaf Walter, Board Member at Octapharma, commented that “Octapharma’s strong presence at the ISTH 2017 Congress reflects our ongoing commitment to improve the lives of patients with coagulation disorders.”
About Haemophilia A
Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.
About von Willebrand disease
VWD is the most common of the inherited bleeding disorders, with approximately 1% of the population having VWF levels below normal. VWD is classified as type 1 (generally mild), type 2 (variable) or type 3 (severe). The symptoms of VWD are usually those of platelet dysfunction and include nose bleeds, skin bruises and haematomas, prolonged bleeds from trivial wounds, oral cavity bleeding, and excessive menstrual bleeding. Gastrointestinal bleeds are relatively rare, but may be very serious when they occur. Severe deficiency of VWF, or a specific defect in the interaction of VWF with FVIII, causes a secondary moderate deficiency of FVIII. These patients may have symptoms that are more characteristic of haemophilia, such as bleeds into joints or soft tissues including muscle and brain.
About Nuwiq ®
Nuwiq® is a natural, long-acting, 4th generation rFVIII protein, produced in a human cell line without chemical modification or fusion with any other protein. Nuwiq® is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs with severe HA, including 59 children. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.
About wilate ®
wilate® is the first double virus inactivated VWF/FVIII, high purity concentrate, utilising the solvent/detergent (S/D) process and Permaheat - a special terminal dry heating (TDH) step. The selected purification processes isolate the VWF/FVIII complex under highly protein protecting conditions, resulting in a 1:1 ratio of VWF:RCo (ristocetin cofactor) to FVIII activity that is similar to normal plasma. No albumin is added as a stabiliser. wilate® is exclusively derived from large pools of human plasma collected in approved plasma donation centres. wilate® contains a VWF triplet structure and content of large high molecular weight multimers similar to normal human plasma. The product is registered in more than 60 countries worldwide, including most EU countries, the US, Canada, Australia, Brazil and Russia.
About octanate ®
octanate® is a human plasma-derived, high-purity, freeze-dried, double virus-inactivated FVIII concentrate for intravenous administration. Coagulation FVIII present in octanate® is bound to its natural stabiliser, von Willebrand factor (VWF), in a VWF/FVIII ratio of approximately 0.4. Therefore, no additional stabilisers are required during manufacturing.
octanate® is used in the prophylaxis and treatment of bleeding in patients with all types of haemophilia A. octanate® is available in 250 IU, 500 IU and 1000 IU presentations. octanate® was first launched in Germany in 1998 and has since been approved in 86 countries. Since its launch, a total of approximately 10 billion IU octanate® have been distributed worldwide. octanate ® is indicated for immune tolerance induction (ITI) in over 40 countries.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.
In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:
· Haematology (coagulation disorders)
· Immunotherapy (immune disorders)
· Critical care
Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.
For more information visit www.octapharma.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Entersekt Partners With ForgeRock20.2.2018 06:00 | Pressemelding
Entersekt, a pioneer in mobile-first authentication and e-commerce enablement, announced today that it has joined the ForgeRock Trust Network as a principal technology partner. ForgeRock is a leading provider of identity and access management solutions to a wide range of industries, including financial services, retail, healthcare, higher education, and communications, in addition to governments like Belgium, Canada, New Zealand, and Norway. Entersekt’s advanced mobile app security, authentication, and digital signing technology is now available to ForgeRock’s customers as a convenient means of securing consumers, citizens, services, and connected devices. Built on open standards, Entersekt’s software integrates seamlessly with omni-channel identity and access management systems like ForgeRock’s. But by aligning closely on a technical and business level, the two companies are better able to unlock value for their shared customer base from product design to support. “As Entersekt did wi
Zonoville Investments Limited Announces Agreement on Acquisition of RUSAL Shares19.2.2018 18:19 | Pressemelding
Zonoville Investments Limited, a consortium of investors led by Renova Group and Access Industries, announced today that it had reached an agreement with Onexim Group to purchase its 6% stake in the United Company RUSAL Plc. Following completion of the purchase, Zonoville Investments Limited and its associate SUAL Partners Limited will hold, in aggregate, approximately a 26.5% interest in United Company RUSAL Plc. About Renova Renova Group of companies (www.renova.ru) is a major private Russian business group which owns and manages assets in metallurgy, mining, chemical, construction, transport, energy, telecommunications, high-tech engineering, public utilities, medicine and financial sectors in Russia and abroad (CIS, Switzerland, Italy, South Africa and the United States of America). Renova’s largest assets include its interests in UC Rusal, T Plus Group, OCTO Telematics and Swiss-based technology concerns Schmolz+Bickenbach, OC Oerlikon, and Sulzer. About Access Industries Founded
The Digital Health Technology Show: The Leading Show for Healthcare Innovation Comes to London19.2.2018 18:05 | Pressemelding
Medical innovation will take centre stage for 2018, at the largest wearables and disruptive health technology event in the world, with never before-seen devices and applications and a raft of industry-leading speakers. The Digital Health Technology Show returns to London on the 13th & 14th March 2018 at London’s Excel, gathering together more than 6,000 attendees and over 100 exhibitors. The 2018 Conference programme boasts three tracks, with over 100 hours of content programmed. Attendees can choose to attend talks on the Digital Health Disrupt Stage – covering global innovation in healthcare, the Leadership Theatre – where senior healthcare figures in the UK will discuss and debate the challenges ahead, or the Patient Engagement Stage – delivering insights into how technology is being used in the real world. There will also be demonstrations of the latest medical innovations on the Innovation Stage, which will also host a start up competition – The Health Innovation Award. Over 200 s
World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London19.2.2018 13:00 | Pressemelding
The latest advances in vaccine safety, reducing unnecessary C-sections and person & patient engagement will be among the varied breakout sessions offered the day after the 6th Annual World Patient Safety, Science & Technology Summit in London by the Patient Safety Movement Foundation. The breakout sessions will convene on Sunday, February 25, 2018 at the prestigious Royal Society, the independent scientific academy of the United Kingdom and the Commonwealth, dedicated to promoting excellence in science. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180219005119/en/ Limited Space available to participate with experts at the 6th Annual World Patient Safety, Science & Technology Summit Break Out Sessions at the Royal Society in London (Photo: Business Wire) The breakout sessions are full-day working meetings structured for shared learning on existing Actionable Patient Safety Solutions (APSS) – collaborative, evidence-based pro
Tampere Attracts AV Productions with a New Incentive19.2.2018 12:41 | Pressemelding
One of the City of Tampere’s strategic goals is to be an international meeting place for creativity and innovation. The development of the experience economy is an essential focus of the city’s business policy. The incentive system is being used to attract more local, national and international productions to the Tampere region. The goal is to promote the development of the industry and to increase the number of jobs and the turnover of commercial productions in Tampere. Through the incentive system, an audiovisual production may recover some of the costs it has spent on wages and service purchases in the Tampere region. A production meeting the incentive criteria may be refunded 10–15 per cent of the accepted costs accrued in the region. Professional productions that utilise the Tampere region as their location or use expertise from the area may apply for the incentive. Thanks to the growing number of productions, Tampere will become more visible in films and TV shows, which will add
Tempo Grows Revenue by 38% in 2017 to $17.9 Million19.2.2018 11:14 | Pressemelding
Tempo, creator of efficiency-enhancing project management software solutions for Atlassian’s Jira platform, announced strong results for its 2017 fiscal year ending December 31, 2017. “2017 marks another productive and successful year for Tempo, with December our highest grossing month ever and sales across our product range exceeding expectations,” commented Agust Einarsson, CEO, “The completion of our new cloud infrastructure and successful migration of our entire customer base to Amazon Web Services (AWS) marks a strategic milestone, empowering Tempo with a more scalable underlying platform and enabling us to deploy products to customers faster.” Highlights for 2017 include: Revenue grew 38% year-over-year to US$17.9 million Almost 2,000 new customers were acquired Launched our new cloud infrastructure Expanded product footprint beyond the Atlassian environment with Tempo for Slack North American operations continued to grow More than 120 partners worldwide Celebrated our 10-year an